Merck KGaA is exercising its option for a global license to commercialize Abbisko Therapeutics Co. Ltd.’s pimicotinib for $85 million. As previously reported by BioWorld, Abbisko out-licensed China ...
The ability of influenza virus to rapidly undergo antigenic shift to evade immunity raises the need for effective influenza antivirals with a broad spectrum. In a recent Nature Microbiology article, ...
Leading pharma companies have pitched into Sofinnova Partners’ new accelerator fund, which has exceeded the target and closed at €165 million (US$180 million). In... Copyright ©2025. All Rights ...
Leading pharma companies have pitched into Sofinnova Partners’ new accelerator fund, which has exceeded the target and closed at €165 million (US$180 million). In... Copyright ©2025. All Rights ...
Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The company also has relacorilant in studies ...
Peter Marks’ March 28 letter giving one week’s notice of his resignation as director of the U.S. FDA’s Center for Biologics Evaluation and Research (CBER) is sending more ripples of uncertainty ...
In the brain, molecular information is transmitted between cells through neural circuits. Synapses establish connections between the pathways that run from one area to another, allowing the most ...
Sun Pharma Advanced Research Co. Ltd. has filed an IND application with the FDA for SBO-154 for the treatment of solid tumors ...
The use of an AI tool could speed up the time it takes to do pregnancy scans by almost half and it is still able to identify any abnormalities in the fetus, researchers found. Results from a study ...
Australia’s Therapeutic Goods Administration floated a draft rule on risk classification for in vitro diagnostics, which does not apply to home use tests, the subject of impending rulemaking.
After announcing that lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD), Opthea has now decided to close the Coast trial as well as ...
Otsuka Pharmaceutical Development & Commercialization Inc. filed its BLA with the U.S. FDA for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN). The company’s first BLA, sibeprenlimab is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback